A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients.
This study evaluates the cost-effectiveness of Omacor treatment as a standard prevention measure post-MI in the UK. A cost-effectiveness model was developed based on the GISSI-P trial, combining a survival and a Markov model, over a lifetime period. The base case results for Omacor, at 4 years and over a lifetime, respectively, were: cost [corrected] per QALY gained: pound15,189 and 3,723; [corrected] cost per life years gained (LYG): pound12,011 and pound2,812 [corrected] The cost per death avoided at 4 years was pound31,786. Deterministic and probabilistic sensitivity analyses did not change the base case results substantially. The use of Omacor as a standard post-MI prevention treatment seems warranted in the UK, both on the basis of its efficacy, which is in addition to other prophylactic treatments as evidenced by the results of the GISSI-P trial, and on cost-effectiveness grounds - both at 4 years and over a lifetime's time-horizon, using the current cost-effectiveness thresholds.
Quilici
S
S
i3 Innovus, Uxbridge, Middlesex, UK. squilici@innovus.com
Martin
M
M
McGuire
A
A
Zoellner
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D003362:Cost-Benefit Analysis; D004281:Docosahexaenoic Acids / Q000191:economics*; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid / Q000191:economics*; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D009203:Myocardial Infarction / Q000191:economics* / Q000401:mortality / Q000517:prevention & control; D019057:Quality-Adjusted Life Years; D016019:Survival Analysis
D004338:Drug Combinations; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C405603:Omacor